Immunovant, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Jacob Bauer

Immunovant, Inc.’s own tally for this item (“Elect Director: Jacob Bauer”): 152,051,231 for, 8,193,169 withheld, per its Form 8-K filed August 28, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 21,243,388 for, 4,845,150 withheld, 3,421 abstained, 54 not voted.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Douglas Hughes

Immunovant, Inc.’s own tally for this item (“Elect Director: Douglas Hughes”): 143,417,281 for, 16,827,119 withheld, per its Form 8-K filed August 28, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors Jacob Bauer, Douglas Hughes and Robert Susman were each elected to serve as a member of Immunovant's Board of Directors (the " Board " ), until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified, by the following vote…”
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 20,706,836 for, 2,983,925 withheld, 2,401,199 abstained, 54 not voted.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Robert Susman

Immunovant, Inc.’s own tally for this item (“Elect Director: Robert Susman”): 159,234,780 for, 1,009,620 withheld, per its Form 8-K filed August 28, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors Jacob Bauer, Douglas Hughes and Robert Susman were each elected to serve as a member of Immunovant's Board of Directors (the " Board " ), until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified, by the following vote…”
Support: 99.3% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 26,091,959 for, 54 not voted.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executive officers.

Immunovant, Inc.’s own tally for this item (“3. Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers”): 158,995,232 for, 1,244,731 against — passed, per its Form 8-K filed August 28, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of Immunovant ' s named executive officers, as disclosed in the Proxy Statement, including the compensati…”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 51 managers: 26,090,320 for, 1,610 against, 54 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 151 managers: 52,765,433 for, 204,105 against, 71,471 abstained, 54 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2026.

Immunovant, Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 165,422,634 for, 7,237 against — passed, per its Form 8-K filed August 28, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant's independent registered public accounting firm for the fiscal year ending March 31, 2026, by th…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 26,091,959 for, 54 not voted.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.